44
Participants
Start Date
July 27, 2018
Primary Completion Date
February 25, 2020
Study Completion Date
February 25, 2020
MNK-1411
MNK-1411 (1 mg/mL suspension) for subcutaneous injection
Placebo
Placebo suspension for subcutaneous injection
University Multiprofile Hospital for Active Treatment Aleksandrovska EAD, Sofia
Clinic of Neurology and Psychiatry for Children and Youth, Belgrade
Ospedale San Raffaele S.r.l. - PPDS, Milan
Rare Disease Research, LLC, Atlanta
NW FL Clinical Research Group, LLC, Gulf Breeze
Mersin Universitesi Tip Fakultesi Hastanesi, Mersin
Instituto de Investigaciones Aplicadas a la Neurociencia A.C., Durango
Monroe Carell Jr Childrens Hospital at Vanderbilt, Nashville
Hospital Civil Fray Antonio Alcalde, Guadalajara
Hospital Universitari i Politecnic La Fe Valencia, Valencia
University of Texas Southwestern Medical Center, Dallas
UT Health Science Center, San Antonio, San Antonio
Neurociencias Estudios Clinicos S.C., Culiacán
Edith Wolfson Medical Center, Holon
Hospital de La Santa Creu i Sant Pau, Barcelona
Hospital Sant Joan de Deu - PIN, Esplugues de Llobregat
Lead Sponsor
Mallinckrodt ARD LLC
INDUSTRY